UBS analyst Kevin Caliendo lowered the firm’s price target on Accendra Health (ACH) to $3 from $4 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACH:
- Tighter CMS Coverage Rules Put Accendra Health’s Non-Invasive Ventilation Revenue and Liquidity at Risk
- Owens & Minor Earnings Call Flags Tough 2026
- Accendra Health Posts 2025 Results, Guides 2026 Outlook
- Accendra Health reports Q4 adjusted EPS 21c, consensus 22c
- Accendra Health sees FY26 revenue $2.55B-$2.65B, consensus $2.6B